NCT00753545 2025-02-03Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian CancerAstraZenecaPhase 2 Completed265 enrolled 25 charts 1 FDA
NCT00516373 2024-02-22A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)AstraZenecaPhase 1 Completed98 enrolled